Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease

Lignende værker

• Advanced Fibrosis is Associated with Incident Cardiovascular Disease in Patients with Non-Alcoholic Fatty Liver Disease
  af: Henson, Jacqueline B., et al.
  Udgivet: (2020)
• Risk of Cardiovascular Disease in Individuals With Nonobese Nonalcoholic Fatty Liver Disease
  af: Ashwini Arvind, et al.
  Udgivet: (2022-02-01)
• The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe
  af: Simon, Tracey G., et al.
  Udgivet: (2018)
• Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis
  af: Wang, Xiaobo, et al.
  Udgivet: (2016)
• Model for end‐stage liver disease Na Score predicts incident major cardiovascular events in patients with nonalcoholic fatty liver disease
  af: Simon, Tracey G., et al.
  Udgivet: (2017)